



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

June 10, 2008 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Physician Update** **7:15 - 7:35**
 - Dr. Scott Strenio from APS – Chronic Care Management Program
- 5. Follow-up Items from Previous Meeting** **7:35 - 7:40**
 - Soliris[®] (eculizumab) for PNH
- 6. Clinical Update: Drug Reviews** **7:40 – 8:00**
(Public comment prior to Board action)
 - Combigan[®] (brimonidine tartrate/timolol maleate) Ophthalmic Solution
 - Simcor[®] (simvastatin/extended-release niacin)
 - Tekturna HCT[®] (aliskiren/hydrochlorothiazide)
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **8:00 – 8:05**
(Public comment prior to Board action)
 - Constipation: Chronic (expanded indication for Amitiza[®] (lubiprostone))
- 8. Drug Classes – Review** **8:05 – 8:15**
 - Urinary Antispasmodics (and new drug review Sanctura XR[®] (trospium XR))
- 9. RetroDUR** **8:15 - 8:45**
 - Asthma Medication Therapy – Pre and Post Emergency Room or Inpatient Hospital Admission
 - Nutritonals, enteral
 - Suboxone[®]/Subutex[®]
- 10. New Drug Product Plan Exclusions (Consent Agenda Topic)** **8:45 - 8:50**
- 11. Updated New-to-Market Drug Monitoring Log** **8:50 - 8:55**

12. General Announcements**8:55 - 9:00****Selected FDA Safety Alerts**

- Inosine Monophosphate Dehydrogenase Inhibitors (IMPDH)
Immunosuppressants – fetal harm/spontaneous abortion
- Enbrel - infection

13. Adjourn**9:00**